Acid sphingomyelinase: a new biomarker for multiple sclerosis?

被引：0
|
作者：
Leurs, C. E. [1 ]
Pinheiro, M. A. Lopes [2 ]
Wierts, L. [2 ]
Eijlers, A. J. C. [3 ]
Balk, L. [1 ]
Wattjes, M. P. [4 ]
Uitdehaag, B. M. J. [1 ]
Killestein, J. [1 ]
de Vries, H. E. [2 ]
机构：
[1] Vrije Univ Amsterdam, Med Ctr, MS Ctr Amsterdam, Neurol, Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, MS Ctr Amsterdam, Mol Cell Biol & Immunol, Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, MS Ctr Amsterdam, Anat & Neurosci,Dept Anat & Neurosci, Amsterdam, Netherlands
[4] Vrije Univ Amsterdam, Med Ctr, MS Ctr Amsterdam, Radiol & Nucl Med, Amsterdam, Netherlands
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1476
引用
收藏
页码：770 / 770
页数：1
相关论文
共 50 条
  • [21] Enhanced release of acid sphingomyelinase-enriched exosomes generates a lipidomics signature in CSF of Multiple Sclerosis patients
    Damiana Pieragostino
    Ilaria Cicalini
    Paola Lanuti
    Eva Ercolino
    Maria di Ioia
    Mirco Zucchelli
    Romina Zappacosta
    Sebastiano Miscia
    Marco Marchisio
    Paolo Sacchetta
    Marco Onofrj
    Piero Del Boccio
    Scientific Reports, 8
  • [22] Identification of hsa_circ_0018905 as a New Potential Biomarker for Multiple Sclerosis
    Lodde, Valeria
    Zarbo, Ignazio Roberto
    Farina, Gabriele
    Masia, Aurora
    Solla, Paolo
    Campesi, Ilaria
    Delogu, Giuseppe
    Muroni, Maria Rosaria
    Tsitsipatis, Dimitrios
    Gorospe, Myriam
    Floris, Matteo
    Idda, Maria Laura
    CELLS, 2024, 13 (19)
  • [23] LOTUS, a possible endogenous inhibitor of axonal degeneration, as a new biomarker for multiple sclerosis
    Takahashi, Keita
    Tanaka, Fumiaki
    Takei, Kohtaro
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2015, 5 (06) : 469 - 472
  • [24] Spinal cord anterior horn atrophy: a new biomarker in progressive multiple sclerosis
    Tsagkas, C.
    Horvath, A.
    Haas, T.
    Cagol, A.
    Amann, M.
    Barakovic, M.
    Ruberte, E.
    Weigel, M.
    Pezold, S.
    Schlaeger, R.
    Sprenger, T.
    Kappos, L.
    Bieri, O.
    Cattin, P.
    Granziera, C.
    Parmar, K.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 393 - 394
  • [25] GFAP in early multiple sclerosis: A biomarker for inflammation
    Kassubek, Rebecca
    Gorges, Martin
    Schocke, Michael
    Hagenston, Viktoria A. M.
    Huss, Andre
    Ludolph, Albert C.
    Kassubek, Jan
    Tumani, Hayrettin
    NEUROSCIENCE LETTERS, 2017, 657 : 166 - 170
  • [26] Endocan, novel potential biomarker for multiple sclerosis?
    Akil, E.
    Alp, R.
    Ozdemir, H. H.
    Arslan, D.
    Cevik, M. U.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 192 - 192
  • [27] MCAM in Multiple Sclerosis: a biomarker of disease activity?
    Muccilli, Alexandra
    Charabati, Marc
    Michel, Laure
    Bourbonniere, Lyne
    Larochelle, Catherine
    Prat, Alexandre
    NEUROLOGY, 2017, 88
  • [28] Proteomics technologies for biomarker discovery in multiple sclerosis
    Singh, Vaibhav
    Hintzen, Rogier Q.
    Luider, Theo M.
    Stoop, Marcel P.
    JOURNAL OF NEUROIMMUNOLOGY, 2012, 248 (1-2) : 40 - 47
  • [29] Serum neurofilament level as a biomarker in multiple sclerosis
    Jabbar, Huda Qate'a
    Hassoun, Hayder K.
    Allebban, Zuhair
    NEUROLOGY ASIA, 2024, 29 (01) : 183 - 191
  • [30] a circulating biomarker for therapeutic response in multiple sclerosis
    Nayak, R.
    Vollmer, T.
    Bomprezzi, R.
    Jacolik, R.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S462 - S462
12345